Načítá se...
Reduction in Use of Risperidone for Dementia in Australia Following Changed Guidelines
Background: Risperidone is the only antipsychotic approved in Australia for the management of the behavioural and psychological symptoms of dementia (BPSD). In June 2015, the Australian Government Therapeutic Goods Administration (TGA) amended the indication to restrict use in BPSD to patients with...
Uloženo v:
| Vydáno v: | Pharmacy (Basel) |
|---|---|
| Hlavní autoři: | , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6789876/ https://ncbi.nlm.nih.gov/pubmed/31336574 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/pharmacy7030100 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|